We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+2.72%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$4.41B
AUM Growth
+$26.8M
Cap. Flow
+$12.3M
Cap. Flow %
0.28%
Top 10 Hldgs %
98.88%
Holding
24
New
1
Increased
1
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
CVRX icon
CVRx
CVRX
+$14.4M
2
LAB icon
Standard BioTools
LAB
+$753K

Top Sells

Rank Stock Value
1
NNOX icon
Nano X Imaging
NNOX
+$1.27M
2
ACET icon
Adicet Bio
ACET
+$838K
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$711K
4
PHGE icon
BiomX
PHGE
+$58.2K
5
APLM icon
Apollomics
APLM
+$12.8K

Sector Composition

Rank Sector Weight
1 Consumer Staples 88.66%
2 Healthcare 11.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVUE icon
1
Kenvue
KVUE
$36.9B
$3.91B 88.66%
182,329,550
– –
FUSN
2
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$78.3M 1.77%
3,670,516
– –
CVRX icon
3
CVRx
CVRX
$78.3M
$74.7M 1.69%
4,103,430
+607,855
+17% +$14.4M
PTGX icon
4
Protagonist Therapeutics
PTGX
$9.8B
$70.9M 1.61%
2,449,183
– –
SWAV
5
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$54.3M 1.23%
166,812
– –
LEGN icon
6
Legend Biotech
LEGN
$3.93B
$45.7M 1.04%
814,586
– –
MGTX icon
7
MeiraGTx Holdings
MGTX
$1.17B
$40.3M 0.91%
6,641,064
– –
NBTX
8
Nanobiotix
NBTX
$1.94B
$36.6M 0.83%
5,623,816
– –
NMRA icon
9
Neumora Therapeutics
NMRA
$321M
$25.4M 0.58%
1,849,445
– –
FATE icon
10
Fate Therapeutics
FATE
$294M
$24.8M 0.56%
3,379,064
– –
PRCT icon
11
Procept Biorobotics
PRCT
$1.26B
$17.7M 0.4%
357,939
– –
XNCR icon
12
Xencor
XNCR
$1.71B
$16.6M 0.38%
748,062
– –
ARWR icon
13
Arrowhead Research
ARWR
$12.1B
$7.08M 0.16%
247,598
– –
VOR icon
14
Vor Biopharma
VOR
$1.38B
$2.55M 0.06%
53,733
– –
NNOX icon
15
Nano X Imaging
NNOX
$73.2M
$1.55M 0.04%
158,852
-158,852
-50% -$1.27M
ALDX icon
16
Aldeyra Therapeutics
ALDX
$86.9M
$980K 0.02%
299,669
– –
PHGE icon
17
BiomX
PHGE
$1.67M
$865K 0.02%
10,122
-1,106
-10% -$58.2K
ACET icon
18
Adicet Bio
ACET
$77.3M
$857K 0.02%
22,780
-20,257
-47% -$838K
LAB icon
19
Standard BioTools
LAB
$294M
$845K 0.02%
+311,967
New +$753K
CLSD
20
DELISTED
Clearside Biomedical
CLSD
$260K 0.01%
11,309
– –
TCON
21
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$36.1K ﹤0.01%
4,200
– –
SENS icon
22
Senseonics Holdings Inc
SENS
$409M
$29K ﹤0.01%
2,731
– –
APLM icon
23
Apollomics
APLM
$38.1M
– –
-133
Closed -$12.8K
SLGC
24
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-281,052
Closed -$711K

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q1 2024 Portfolio in Review

As of Q1 2024, Johnson & Johnson held 24 positions worth $4.41B, up 0.61% from $4.39B the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson's Q1 2024 filing shows 1 new, 1 increased, 3 reduced and 2 closed positions. Its largest new stake was Standard BioTools: 311,967 shares worth $845K. The largest sale was Nano X Imaging, an estimated $1.27M.

By sector, the portfolio is most concentrated in Consumer Staples at 89% of assets, down from 89% a quarter earlier, followed by Healthcare.

  • Johnson & Johnson's largest Q1 2024 buy was Standard BioTools: 311,967 shares worth $845K.
  • Johnson & Johnson added most to CVRx in Q1 2024, an estimated $14.4M increase.
  • Johnson & Johnson's biggest Q1 2024 reduction was Nano X Imaging, cutting an estimated $1.27M.
  • Johnson & Johnson fully exited SomaLogic, Inc. Class A Common Stock in Q1 2024, selling an estimated $711K.
  • Johnson & Johnson's ten largest holdings make up 99% of its $4.41B portfolio in Q1 2024.
  • Johnson & Johnson opened 1 new position and closed 2 in Q1 2024.
  • Johnson & Johnson's portfolio value rose 0.61% quarter-over-quarter to $4.41B.

Based on Johnson & Johnson's 13F filing for Q1 2024, filed 10 May 2024.